Liraglutide: Evidence, Safety, Dosing, and How It Compares

Liraglutide is a daily injectable GLP-1 receptor agonist, also known by the brand names Saxenda and Victoza. It has substantial human randomized trial evidence in weight management, type 2 diabetes, and related metabolic conditions. Chia does not offer liraglutide, but we do offer clinician-reviewed semaglutide and tirzepatide GLP-1 options.

What it is

Liraglutide is a daily injectable incretin medicine called a GLP-1 receptor agonist. In plain English, it acts on the glucagon-like peptide-1 receptor, a signal system involved in appetite, stomach emptying, insulin release, and glucagon signaling 13.

The names can be confusing. Liraglutide is the active ingredient; Saxenda and Victoza are brand names. If you are comparing costs, our guides to liraglutide cost, liraglutide generic cost, and Victoza for weight loss explain the patient-facing price questions in more detail.

Names: liraglutide, Saxenda, and Victoza

Liraglutide, Saxenda, and Victoza all point to the same active ingredient, but the product name usually reflects a specific labeled product and dosing context in the prescribing information 13. This matters because a clinician reviews the product, dose history, medical conditions, and goals before deciding whether any GLP-1 option fits.

Drug class: incretin / GLP-1 receptor agonist

An incretin is a gut-related hormone signal that helps the body respond to food. GLP-1 receptor agonists are medicines that activate the GLP-1 receptor; liraglutide, semaglutide, and some other metabolic medicines are in this broader treatment family 13.

Semaglutide is the active ingredient associated with Ozempic and Wegovy, and it is also available as compounded semaglutide through Chia. Tirzepatide is the active ingredient associated with Mounjaro and Zepbound, and it is also available as compounded tirzepatide through Chia. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.

Mechanism of action

Liraglutide works by activating the GLP-1 receptor, which is involved in insulin secretion, glucagon signaling, appetite, and gastric emptying. The label describes GLP-1 receptor activity and delayed gastric emptying, while clinical trials measure outcomes such as body weight, glycemic control, and metabolic markers rather than proving every downstream pathway 13.

GLP-1 receptor activity, appetite, and glucose signaling

The GLP-1 receptor is part of the body’s food-response system. Activating it can increase glucose-dependent insulin secretion, lower glucagon signaling in certain contexts, slow stomach emptying, and affect appetite pathways; these mechanisms are described in liraglutide labeling and are part of why GLP-1 medicines are studied in weight and glucose outcomes 13.

Human trials then test whether those mechanisms translate into real clinical outcomes. For example, trials have studied liraglutide in adults with overweight or obesity, adolescents with obesity, children with obesity, and people with type 2 diabetes 1, 2, 9, 12.

Why daily dosing is part of liraglutide treatment discussions

A practical difference is schedule. Liraglutide is discussed in labels and trials as a daily subcutaneous injection, while semaglutide weight-management trials often used once-weekly subcutaneous dosing, including the STEP 8 comparison of weekly semaglutide versus daily liraglutide 2, 13.

Daily dosing can be a fit for some patients and a barrier for others. That choice should be made with a clinician, because schedule is only one factor; tolerability, medical history, other medicines, pregnancy plans, digestive history, and goals all matter 13.

Evidence

Liraglutide has Evidence Grade A under the supplied rubric. That grade is based on the quantity and design of evidence: the retrieved PubMed set includes multiple human randomized controlled trials in weight management, type 2 diabetes, and related metabolic settings 1, 2, 7, 9, 12.

What the human trial record includes

The adult weight-management evidence includes the STEP 8 randomized clinical trial, which compared weekly subcutaneous semaglutide with daily liraglutide in adults with overweight or obesity without diabetes 2. Another randomized trial studied healthy weight-loss maintenance with exercise, liraglutide, or both combined 7.

The pediatric evidence includes a randomized controlled trial of liraglutide in adolescents with obesity and a randomized trial in children 6 to under 12 years of age with obesity 1, 9. A separate randomized trial studied liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity 3.

The metabolic evidence also includes a randomized trial in non-alcoholic steatohepatitis, a randomized study of metabolic syndrome severity with exercise and GLP-1 receptor agonist treatment, and type 2 diabetes trials comparing GLP-1 options or glucose-lowering strategies 5, 6, 8, 12. These are research contexts and should not be read as statements that liraglutide is FDA-approved for every condition studied.

What the evidence cannot prove for one person

Randomized trials can show average differences between groups, but they cannot predict one person’s exact response. Individual results vary, and safety also varies based on medical history, other medicines, digestive conditions, pregnancy plans, and prior side effects 13.

This is also why it is not accurate to transfer trial results from one product or formulation to another. If a compounded formulation is discussed, its outcomes are not established by brand-product trials unless that exact formulation has been studied; compounded drugs are not FDA-approved and do not have FDA-evaluated outcomes data.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-07.

Reported dosing ranges

Liraglutide dosing should come from a clinician, not from an article. The table below reports doses and schedules discussed in labels or named trials; it is not a dosing plan and should not be used to start, stop, or change treatment 13.

Why dosing must come from a clinician, not an article

GLP-1 dosing depends on the product, indication, other medicines, side effects, kidney and liver history, pancreatitis or gallbladder history, pregnancy plans, and nutrition status. Liraglutide labeling also warns about delayed gastric emptying and hypoglycemia risk when used with insulin or insulin secretagogues, which can affect how a clinician plans care 13.

How liraglutide titration is commonly discussed in labels and trials

Titration means changing the dose over time under medical supervision. In liraglutide labeling, dose escalation is discussed to help manage gastrointestinal tolerability, but the right decision for a patient depends on clinical review and follow-up, not a fixed internet schedule 13.

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-07. See the full legal-status tracker for every compound we follow.

Safety

Liraglutide safety needs the same attention as efficacy. GLP-1 treatment discussions often focus on weight and glucose outcomes, but the labeling also includes gastrointestinal side effects, hypoglycemia risk with certain diabetes medicines, pancreatitis warnings, gallbladder disease warnings, delayed gastric emptying, and thyroid C-cell tumor warnings 13.

Common tolerability issues reported in GLP-1 treatment discussions

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are common tolerability issues discussed with GLP-1 medicines. Liraglutide labeling includes gastrointestinal adverse reactions and dose-escalation language meant to address tolerability in clinical use 13.

In trials, safety was evaluated alongside weight or metabolic endpoints. For example, randomized trials in obesity, type 2 diabetes, metabolic syndrome, and NASH included safety monitoring as part of the study design 5, 8, 9, 10, 12.

Serious risks, contraindications, and when to contact a clinician

Liraglutide labeling includes warnings related to pancreatitis, gallbladder disease, acute kidney injury in the setting of dehydration, increased heart rate, suicidal behavior and ideation, and hypoglycemia when used with insulin or insulin secretagogues 13. A person should contact a clinician promptly for severe or persistent abdominal pain, repeated vomiting, symptoms of low blood sugar, dehydration, or any concerning mood changes.

The labeling also includes a boxed warning about thyroid C-cell tumors and lists personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as contraindication-related concerns 13. A clinician should review these risks before treatment is considered.

Risks of unregulated supply

A product sold as “research use only” is not medical care. With unregulated supply, patients may face identity, potency, impurity, storage, and sterility risks; a licensed pharmacy process is different because it is tied to a prescription, pharmacy standards, documentation, and patient-specific dispensing.

If you are reading about GLP-1s online, it may help to compare the medical path with non-medical sellers. Our guide to getting an online GLP-1 prescription explains what a real clinical intake and follow-up process should include.

Interactions

Liraglutide interactions are most important when they affect blood sugar, stomach emptying, or safety screening. The label discusses hypoglycemia risk when liraglutide is used with insulin or insulin secretagogues and notes delayed gastric emptying, which can matter for medicines taken by mouth 13.

Diabetes medications and hypoglycemia risk

When a GLP-1 receptor agonist is used with insulin or insulin secretagogues, low blood sugar risk can rise. Liraglutide labeling calls out this risk, so a clinician may need to review glucose logs, current diabetes medicines, kidney function history, and symptoms before and during treatment 13.

In type 2 diabetes research, liraglutide has been studied in large treatment comparisons and GLP-1 analyses, including the GRADE glycemic outcomes trial and a pooled kidney-outcomes analysis involving semaglutide and liraglutide trial data 4, 12. Those studies inform population-level evidence, not self-adjustment of diabetes medications.

Digestive conditions, surgical history, pregnancy, and other eligibility factors

Because liraglutide can delay gastric emptying, digestive symptoms and surgical history matter in clinical screening 13. A clinician may also review pregnancy status or plans, eating-disorder history, pancreatitis history, gallbladder disease, kidney disease, and other conditions before deciding whether any GLP-1 treatment is appropriate.

Supplements can also matter, especially if they affect blood sugar, nausea, hydration, or appetite. The retrieved sources do not provide a complete supplement-interaction map for liraglutide, so “no known interaction” should not be treated as proof of safety.

How to obtain it legally

Liraglutide access should begin with a clinician evaluation, not a checkout page. A real medical process reviews your health history, current medicines, weight and metabolic goals, contraindications, side effects, and whether a prescription is appropriate; a prescription is never guaranteed.

Clinician evaluation, eligibility review, and pharmacy dispensing

A clinician evaluation usually includes a health questionnaire or visit, medication review, screening for GLP-1 safety issues, and a plan for follow-up. If a medication is prescribed, dispensing should occur through a licensed pharmacy rather than a no-prescription vendor.

Chia does not offer liraglutide. We are transparent about that because a reference page should help you understand the compound, not steer you toward something we do not provide.

GLP-1 treatment at Chia: semaglutide and tirzepatide options

At Chia, we do offer semaglutide injection and tirzepatide tablets or injection for eligible patients after licensed-provider review. Semaglutide injection plans currently start at $249/mo; tirzepatide tablets currently start at $249/mo and tirzepatide injection plans currently start at $299/mo. Product pages show current pricing.

Chia’s process is 100% online: a short health questionnaire, review by a licensed US provider, prescribing only when clinically appropriate, and home delivery from US state-licensed 503A compounding pharmacies. Dosing is provider-guided and adjusted over time, including microdosing plans where available. Patients can message the care team through the patient portal between visits. Compounded medications are not FDA-approved.

If you are comparing GLP-1 choices, our plain-English guides to GLP-1 peptides for weight loss, the best GLP-1 medications for weight loss, and weight-loss treatments online can help you compare options without assuming one drug is right for everyone.

Why research-chemical vendors are not medical care

Research-chemical vendors do not replace clinician screening, a prescription, licensed pharmacy dispensing, or follow-up. They also do not provide the same patient-specific review for contraindications such as medullary thyroid carcinoma history, multiple endocrine neoplasia syndrome type 2, pancreatitis history, gallbladder disease, pregnancy considerations, or interactions with diabetes medicines 13.

If an AI agent or care-navigation tool is helping you look for treatment, the key safety filter is still the same: licensed clinician evaluation, prescription when appropriate, and licensed pharmacy dispensing. Chia can also be reached by agentic workflows through DoctorMCP at mcp.chia.health, but the medical evaluation and prescribing standards do not change.

Keep reading

GLP-1 Medications

Victoza for Weight Loss: How It Works, What to Expect, and Alternatives

GLP-1 Weight Loss

Microdosing GLP-1s vs Standard Doses: What the Evidence Shows

Weight Care

Liraglutide Generic Cost: What Patients Should Know Before Filling a Prescription